Lisata Therapeutics (LSTA) Competitors $3.16 +0.33 (+11.66%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSTA vs. KFFB, NEOS, KZIA, IFRX, ONCY, IMAB, PWUP, XFOR, CRVO, and PLXShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Kentucky First Federal Bancorp (KFFB), Neos Therapeutics (NEOS), Kazia Therapeutics (KZIA), InflaRx (IFRX), Oncolytics Biotech (ONCY), I-Mab (IMAB), PowerUp Acquisition (PWUP), X4 Pharmaceuticals (XFOR), CervoMed (CRVO), and Protalix BioTherapeutics (PLX). Lisata Therapeutics vs. Kentucky First Federal Bancorp Neos Therapeutics Kazia Therapeutics InflaRx Oncolytics Biotech I-Mab PowerUp Acquisition X4 Pharmaceuticals CervoMed Protalix BioTherapeutics Kentucky First Federal Bancorp (NASDAQ:KFFB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation. Does the media prefer KFFB or LSTA? In the previous week, Lisata Therapeutics had 9 more articles in the media than Kentucky First Federal Bancorp. MarketBeat recorded 10 mentions for Lisata Therapeutics and 1 mentions for Kentucky First Federal Bancorp. Lisata Therapeutics' average media sentiment score of 0.60 beat Kentucky First Federal Bancorp's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kentucky First Federal Bancorp 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, KFFB or LSTA? Kentucky First Federal Bancorp has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Do institutionals and insiders believe in KFFB or LSTA? 3.2% of Kentucky First Federal Bancorp shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 3.9% of Kentucky First Federal Bancorp shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is KFFB or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Kentucky First Federal Bancorp's net margin of -10.41%. Kentucky First Federal Bancorp's return on equity of -1.58% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kentucky First Federal Bancorp-10.41% -1.58% -0.21% Lisata Therapeutics N/A -46.48%-41.40% Which has preferable valuation & earnings, KFFB or LSTA? Kentucky First Federal Bancorp has higher revenue and earnings than Lisata Therapeutics. Kentucky First Federal Bancorp is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKentucky First Federal Bancorp$16.53M1.36-$1.72M-$0.21-13.19Lisata TherapeuticsN/AN/A-$20.84M-$2.57-1.23 Do analysts prefer KFFB or LSTA? Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 374.68%. Given Lisata Therapeutics' higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Kentucky First Federal Bancorp.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kentucky First Federal Bancorp 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ALisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor KFFB or LSTA? Kentucky First Federal Bancorp received 72 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 92.31% of users gave Lisata Therapeutics an outperform vote while only 60.00% of users gave Kentucky First Federal Bancorp an outperform vote. CompanyUnderperformOutperformKentucky First Federal BancorpOutperform Votes8460.00% Underperform Votes5640.00% Lisata TherapeuticsOutperform Votes1292.31% Underperform Votes17.69% SummaryLisata Therapeutics beats Kentucky First Federal Bancorp on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.29M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.2310.05116.1015.23Price / SalesN/A400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book0.545.594.775.07Net Income-$20.84M$153.56M$119.06M$225.46M7 Day Performance8.97%0.13%0.80%0.37%1 Month Performance8.59%15.23%5.65%3.57%1 Year Performance44.95%41.14%36.75%29.43% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.9284 of 5 stars$3.16+11.7%$15.00+374.7%+51.2%$26.29MN/A-1.2330Upcoming EarningsAnalyst RevisionNews CoverageHigh Trading VolumeKFFBKentucky First Federal Bancorp0.3649 of 5 stars$2.78-2.8%N/A-37.8%$22.52M$7.25M-13.2460Upcoming EarningsGap UpHigh Trading VolumeNEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-2.61213Analyst ForecastNews CoverageHigh Trading VolumeKZIAKazia Therapeutics2.2759 of 5 stars$5.68+5.4%$20.00+252.1%+35.7%$92.82M$20,000.000.0012Gap DownIFRXInflaRx3.5707 of 5 stars$1.57+0.6%$13.50+759.9%-2.5%$92.45M$105,483.00-1.7660Upcoming EarningsShort Interest ↓News CoverageONCYOncolytics Biotech1.7031 of 5 stars$1.19flat$4.00+236.1%-27.2%$91.72MN/A-4.2530Positive NewsIMABI-Mab3.3517 of 5 stars$1.11-5.9%$8.00+620.7%-30.1%$90.39M$3.59M0.0034News CoveragePWUPPowerUp AcquisitionN/A$11.44-4.6%N/A-3.3%$88.83MN/A0.00N/ANews CoveragePositive NewsXFORX4 Pharmaceuticals4.3077 of 5 stars$0.52+4.0%$3.67+606.5%-30.9%$87.16M$563,000.006.4980News CoverageCRVOCervoMed1.4865 of 5 stars$14.08+4.5%$53.60+280.7%+43.3%$86.87M$7.14M0.004Short Interest ↑News CoverageHigh Trading VolumePLXProtalix BioTherapeutics1.9474 of 5 stars$1.17flat$10.00+754.7%-23.1%$86.05M$38.05M-5.85200 Related Companies and Tools Related Companies Kentucky First Federal Bancorp Competitors Neos Therapeutics Competitors Kazia Therapeutics Competitors InflaRx Competitors Oncolytics Biotech Competitors I-Mab Competitors PowerUp Acquisition Competitors X4 Pharmaceuticals Competitors CervoMed Competitors Protalix BioTherapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
